Lakefront Biotherapeutics (GLPGF) Receivables (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Receivables for 14 consecutive years, with $159.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables fell 7.68% year-over-year to $159.6 million in Q1 2026; TTM through Mar 2026 was $159.6 million, a 7.68% decrease from a year earlier, with the FY2025 full-year figure at $166.5 million, down 14.64% from the prior year.
• Receivables was $159.6 million for Q1 2026 at Lakefront Biotherapeutics, down from $171.5 million in the prior quarter.
• Over five years, Receivables peaked at $41.4 billion in Q4 2022 and troughed at $159.6 million in Q1 2026.
• A 5-year average of $3.4 billion and a median of $192.6 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables sank 99.56% in 2023 and rose 21.76% in 2024, its largest moves.
• Over 5 years, Receivables stood at $41.4 billion in 2022, then slumped by 99.56% to $182.6 million in 2023, then gained by 5.46% to $192.6 million in 2024, then declined by 10.92% to $171.5 million in 2025, then retreated by 6.97% to $159.6 million in 2026.
• The last three Receivables figures came in at $159.6 million (Q1 2026), $171.5 million (Q4 2025), and $189.8 million (Q3 2025), per Business Quant data.